Evercore ISI raised the firm’s price target on Bath & Body Works to $45 from $30 and keeps an In Line rating on the shares. Street margin estimates for FY24 were “way too high coming out of last quarter,” though management did a good job of resetting margin estimates to “much more realistic levels,” the analyst tells investors. While Bath & Body has “several exciting initiatives in the hopper that could be potential catalysts for shares,” the firm remains on the sidelines because it notes guidance is still predicated on back half inflection and the expectation for such an inflection remains a risk.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBWI:
- BBWI Earnings: Bath & Body Works Plunges on Dismal Outlook
- Bath & Body Works Unveils Q4 and Annual Financials with 2024 Guidance
- Bath & Body Works Reports Fourth Quarter and Full-Year 2023 Results and Provides 2024 Outlook
- Bath & Body Works sees Q1 EPS 28c-33c, consensus 39c
- Bath & Body Works sees FY24 EPS $3.00-$3.35, consensus $3.34